In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Sempra's current price exceeds the PERT-weighted fair value by 23.6%, signaling potential overvaluation despite high-confidence valuation inputs. Conflicting valuation methods range widely, from heavy negative DCF values to strong analyst targets near $110. Financial health scores indicate fair liquidity but weaknesses in efficiency and growth, implying moderate risk amid optimistic price levels.